Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

State of the Science Summit - Gynecologic Cancers: Chaired Mario M. Leitao, Jr., MD, FACOG, FACS

February 1st 2024

State of the Science Summit - Gynecologic Cancers: Chaired Mario M. Leitao, Jr., MD, FACOG, FACS

HER2 ADCs in Cervical Cancer: A Promising Therapeutic Frontier

February 1st 2024

Ritu Salani, MD, highlights impactful findings from the DESTINY-PanTumor02 study in patients with cervical cancer, highlighting the promising role of HER2-directed ADCS in this treatment space.

HER2 ADCs in Endometrial Cancer: Shaping the Treatment Landscape

February 1st 2024

Ritu Salani, MD, discusses impactful efficacy signals from T-DXd in the DESTINY-PanTumor02 study for endometrial cancer, marking a potential breakthrough in this treatment field.

Dr Salani on the De-Escalation of Therapy in Gynecologic Oncology

January 29th 2024

Ritu Salani, MD, discusses the de-escalation of therapy and unmet needs within the landscape of gynecologic oncology.

Onvansertib Induces Preclinical Anti-Tumorigenic Effects in Endometrioid Endometrial Cancer

January 27th 2024

Nikita Sinha, MD, discusses the effects of onvansertib on cellular proliferation, adhesion, apoptosis, and stress in endometrial cancer cells.

SGO Winter Meeting Spotlights Key Developments and Debates Across Gynecologic Oncology

January 26th 2024

Ritu Salani, MD, provides an overview of the variety of sessions presented at the 2024 SGO Winter Meeting.

Dr. Sinha on the Antitumor Effects of Onvansertib in a Preclinical Endometroid Endometrial Cancer Model

January 26th 2024

Nikita Sinha, MD, discusses the potential effects of onvansertib on endometroid endometrial cancer pathogenesis in a preclinical model.

Preclinical Study Reveals Potential Role for GLP Agonists in Endometrial Cancer

January 26th 2024

Danielle Krause, MD, discusses preclinical findings from mouse models evaluating GLP-1 agonists with and without progesterone in endometrial cancer.

Toxicities From Lenvatinib/Pembrolizumab Associated With Treatment Response in Gynecologic Malignancies

January 26th 2024

Paulina J. Haight, MD, discusses the association between the occurrence of toxicities with response to treatment with lenvatinib and pembrolizumab.

Dr Krause on GLP-1 Receptor Agonist Therapy in Endometrial Cancer

January 26th 2024

Danielle Krause, MD, discusses the effects of GLP-1 receptor agonist therapy in endometrial cancer.

Dr Haight on Predictors of Treatment Toxicity in Gynecologic Malignancies

January 26th 2024

Paulina J Haight, MD, discusses predictors of toxicity and treatment response with lenvatinib and pembrolizumab in patients with gynecologic malignancies.

Emerging Data for HER2 ADCs in Ovarian Cancer

January 25th 2024

Ritu Salani, MD, presents an outline of the treatment landscape for ovarian cancer and underscores encouraging data from the DESTINY-PanTumor02 study, showcasing promising results in this treatment setting.

Landscape Surrounding HER2 ADCs in GI Cancers

January 25th 2024

Martin Dietrich, MD, PhD, discusses the role of HER2 ADCs in GI cancers, reviewing key data from DESTINY-Gastric and DESTINY-CRC trials.

The Role of Genetics in Cancer Care Continues to Expand

January 18th 2024

Genetic screening and testing have only recently become an integral part of cancer care.

Targeting HER2 Alterations with ADCs in NSCLC

January 18th 2024

Martin Dietrich, MD, PhD, examines the safety and efficacy of HER2-directed ADCs in NSCLC, emphasizing significant differences in response associated with HER alterations.

Expert Insights on HER2-Directed ADCs in Breast Cancer

January 18th 2024

Martin Dietrich, MD, PhD, offers a comprehensive review of the efficacy and safety of HER2 ADCs in breast cancer, underscoring their substantial impact on treatment practices in both HER2+ and HER2-low.

Future Directions in the Treatment of Recurrent or Metastatic Cervical Cancer

January 17th 2024

The panel closes their discussion by highlighting challenges in the treatment of cervical cancer, emphasizing the need for more focus on clinical trials and therapies, as well as addressing disparities in cancer care, particularly for patients of color.

ESMO 2023 Updates in Endometrial and Cervical Cancer Give Glimpse Into Future Care

January 15th 2024

Updated data from several clinical trials in endometrial and cervical cancer could signal the emergence of multiple effective options coming down the pike.

FDA Approves Pembrolizumab Plus Chemoradiation for FIGO 2014 Stage III to IVA Cervical Cancer

January 12th 2024

The FDA has approved pembrolizumab (Keytruda) plus chemoradiation for patients with FIGO 2014 stage III to IVA cervical cancer.

HER2 in Breast Cancer: Shaping Treatment in Other Solid Tumors

January 11th 2024

Martin Dietrich, MD, PhD, reflects on the lessons and insights gleaned from HER2 in breast cancer, examining their influence on the development of treatment approaches utilizing HER2-targeted therapies in other solid tumors.